Paratek to acquire Optinose and its nasal spray Xhance
Paratek Pharmaceuticals is expanding beyond antibiotics and infectious disease by paying up to $330 million to acquire Optinose and its drug-device combination for chronic rhinosinusitis (CRS). Paratek will obtain Optinose’s Xhance, which features its so ...
Paratek Pharmaceuticals is expanding beyond antibiotics and infectious disease by paying up to $330 million to acquire Optinose and its drug-device combination for chronic rhinosinusitis (CRS).
Paratek will obtain Optinose’s Xhance, which features its so ...
